Lack of progress in cardiogenic shock: Lessons from the GUSTO trials

European Heart Journal

Volumn 21, Issue 23, 2000, Pages 1928-1936

  Menon, Venu ^a,h   Hochman, J S ^a   Stebbins, A ^b   Pfisterer, M ^c   Col, J ^d   Anderson, R D ^b   Hasdai, D ^e   Holmes Jr , D R ^e   Bates, E R ^f   Topol, E J ^g   Califf, R M ^b   Ohman, E M ^b  

^a Howard Hughes Medical Institute   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Mortality; Myocardial infarction; Shock; Thrombolysis

Indexed keywords

ALTEPLASE; ANTITHROMBIN; FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0033679339     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2240     Document Type: Article

References (24)

1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
2. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction
3. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
4. The German multi-center trial of anisoylated streptokinase activator complex versus heparin for acute myocardial infarction
5. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET)
6. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience
7. Frequency of inclusion of patients with cardiogenic shock in clinical trials
8. A comparison of reteplase with alteplase for acute myocardial infarction
9. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
10. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction
11. Activated partial thromboplastin time and outcomes after thrombolytic therapy for acute myocardial infarction; results from the GUSTO-I trial
12. Predictors of 30 day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators
13. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of mortality and major morbidity results from all randomized trials of more than 1000 patients
14. Temporal trends in cardiogenic shock complicating acute myocardial infarction
15. Differences in countries use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction
16. The effectiveness of right heart catheterization in the initial care of critically ill patients
17. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent
18. Arterial diastolic blood pressure augmentation by intraaortic balloon counterpulsation enhances the onset of coronary reperfusion by thrombolytic therapy
19. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-I study
20. Intraaortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction
21. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry
22. In hospital mortality and clinical course of 20 861 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
23. Early revascularization in acute myocardial infarction complicated by cardiogenic shock
24. Effect of early revascularization for cardiogenic shock on 1 year mortality; the SHOCK trial results